Page 98 - Read Online
P. 98

Page 4 of 10                           Toihata et al. J Cancer Metastasis Treat 2018;4:24  I  http://dx.doi.org/10.20517/2394-4722.2017.82

               RAINBOW trial showed a significant benefit of ramucirumab for advanced EGJ and gastric adenocarcinoma,
               as the second-line chemotherapy.


               The REGARD trial [phase III, including advanced EGJ (n = 90) and gastric adenocarcinoma (n = 265)]
               exhibited a significant benefit of ramucirumab (OS 5.2 months for ramucirumab vs. OS 3.8 months for
               placebo; HR 0.776, 95% CI 0.603-0.998; P = 0.047). However, in a subgroup analysis of EGJ adenocarcinoma,
               the trial did not exhibit any significant benefit of ramucirumab (ramucirumab groups vs. placebo groups,
               HR 0.76; 95% CI 0.47-1.21). The incidence of hypertension was higher in the ramucirumab group than in
                                         [14]
               the placebo group (16% vs. 8%) . In the RAINBOW trial [phase III, including advanced EGJ (n = 137) and
               gastric adenocarcinoma (n = 528)], the ramucirumab plus paclitaxel conferred a significantly prolonged OS,
               compared to the placebo plus paclitaxel group (9.6 vs. 7.4 months, HR 0.807; 95% CI 0.678-0.962; P = 0.017).
               In a subgroup analysis of EGJ adenocarcinoma, the trial revealed survival benefit of adding ramucirumab,
               either (ramucirumab plus paclitaxel groups vs. placebo plus paclitaxel groups, HR 0.39; 95% CI 0.26-0.59).
               Grade 3 or 4 adverse events that occurred in more than 5% of patients in the ramucirumab and paclitaxel
               group vs. placebo and paclitaxel group were as follow; neutropenia (41% vs. 19%), leucopenia (17% vs. 7%),
                                                                                                  [7]
               hypertension (14% vs. 2%), fatigue (12% vs. 5%), anemia (9% vs. 10%), and abdominal pain (6% vs. 3%) .
               Bevacizumab (anti-VEGF antibody)
               Bevacizumab, which is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A),
               inhibiting tumor growth in preclinical studies [15,16] . In AVAGAST trial [phase III, including advanced EGJ
               (n = 103) and gastric adenocarcinoma (n = 671)], bevacizumab did not confer any survival benefit (median
               OS 12.1 months in bevacizumab plus XP; vs. median OS 10.1 months in XP alone). In a subgroup analysis of
                                                                          [17]
               EGJ adenocarcinoma, there was no survival benefit (data not available) .
               Lapatinib
               Lapatinib is the dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth
               factor receptor 2 (HER2) tyrosine kinases. In the TRIO-013/LOGiC trial [phase III, including advanced EGJ
               (n = 46), esophageal (n = 20) and gastric adenocarcinoma (n = 424)], lapatinib plus capecitabine and oxaliplatin
               (CapeOX) showed no additional efficacy as the first-line treatment for HER2 positive patients [median OS
               12.2 months in CapeOX + lapatinib groups (95% CI 10.6-14.2) vs. median OS 10.5 months in CapeOX groups
               (95% CI 9.0-11.3), HR 0.91; 95% CI 0.73-1.12; P = 0.35]. In a subgroup analysis of EGJ adenocarcinoma, there
                                                                                                       [18]
               was no survival benefit (CapeOX + lapatinib groups vs. CapeOX groups, HR 0.90; 95% CI 0.44-1.85; P = 0.77) .
               TyTan study [phase III, including advanced EGJ (n = 2) and gastric adenocarcinoma (n = 259)] demonstrated
               that lapatinib plus paclitaxel did not improve OS in HER2-positive patients compared to paclitaxel alone
               [median OS 11.0 months in lapatinib plus paclitaxel group (95% CI 9.5-14.5) vs. median OS 8.9 months in
                                                                                [19]
               paclitaxel alone group (95% CI 7.4-11.1), HR 0.84; 95% CI 0.64-1.11; P = 0.1044] .

               Cetuximab, or panitumumab (anti-EGFR antibody)
               Cetuximab is an EGFR antibody, widely used for patients with KRAS wild-type metastatic colorectal
                                                                                      [22]
               cancer [20,21] , recurrence or metastatic squamous-cell carcinoma of the head and neck , and advanced non-
                                  [23]
               small-cell lung cancer . In the EXPAND trial [phase III, including advanced EGJ (n = 144) and gastric
               adenocarcinoma (n = 747)], the efficacy of adding cetuximab to capecitabine plus cisplatin was examined.
               However, there was no benefit to adding of cetuximab to chemotherapy compared to chemotherapy alone
               in the first-line treatment [median PFS 4.4 months in cetuximab plus capecitabine and cisplatin groups
               (95% CI 4.2-5.5); vs. median PFS 5.6 months in capecitabine and cisplatin alone groups (95% CI 5.1-5.7); HR
               1.09; 95% CI 0.92-1.29; P = 0.32]. In a subgroup analysis of EGJ adenocarcinoma, there was no benefit to add
               cetuximab, either [median PFS 5.6 months in cetuximab plus capecitabine and cisplatin groups vs. median
                                                                                      [24]
               PFS 5.6 months in capecitabine and cisplatin alone groups; HR 1.12; 95% CI 0.73-1.71] .
   93   94   95   96   97   98   99   100   101   102   103